Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Beats Expectations By $0.33 EPS

Incyte (NASDAQ:INCY) issued its earnings results on Thursday. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33, FiscalAI reports. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the previous year, the company earned $2.26 EPS. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year.

Here are the key takeaways from Incyte’s conference call:

• Strong quarterly performance and raised guidance: Third-quarter revenue and net sales both increased 14% year over year to $1.56 billion and $1.32 billion, respectively. Incyte raised full-year 2026 net sales guidance to $5.21 billion–$5.30 billion, driven by OPZELURA and hematology/oncology products.
• OPZELURA continued to drive growth: OPZELURA sales rose 36% to $255 million, with underlying U.S. demand up 24% on a pro forma basis and strong new-patient growth. European approval for moderate atopic dermatitis and potential additional HS applications could further expand the franchise.
• Late-stage pipeline advanced across multiple therapeutic areas: Incyte highlighted encouraging early data for its G12D inhibitor in pancreatic and colorectal cancer and its TGFβR2×PD-1 bispecific in colorectal cancer. The company now has six Phase III programs and expects additional data and regulatory milestones over the next 12–18 months.
• CALR-directed MPN program remains a major value driver: Management expects to present more mature frontline data for INCA033989 at ASH and plans to advance a potentially more potent, longer-acting next-generation CALR antibody into the clinic in early 2027. The company is also discussing alternative composite endpoints with the FDA that could better capture disease modification.
• Pipeline investment and portfolio pruning create near-term risks: GAAP operating expenses surged 146%, largely due to the $1.23 billion Vega acquisition-related R&D charge, while the company discontinued enrollment in the Phase III platinum-resistant ovarian cancer study for its CDK2 inhibitor. Jakafi sales grew only 4% because of pricing effects, and management continues to prepare for retaining only 10%–30% of the franchise by 2029.

Incyte Trading Down 0.1%

INCY opened at $116.80 on Friday. Incyte has a 1-year low of $89.25 and a 1-year high of $132.60. The stock has a market capitalization of $23.68 billion, a PE ratio of 14.88, a PEG ratio of 4.83 and a beta of 0.74. The firm has a 50-day moving average price of $120.62 and a two-hundred day moving average price of $108.07.

Insider Activity

In other news, insider Pablo Cagnoni sold 10,801 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the sale, the insider directly owned 183,200 shares of the company’s stock, valued at $23,002,592. This represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, beating the roughly $1.46 billion consensus estimate. The adjusted loss of $3.60 per share was also narrower than analysts expected. Incyte Q3 earnings report
• Positive Sentiment: Underlying product performance was strong: Opzelura sales increased 36% to $255 million, Hematology and Oncology sales rose 38% to $235 million, and Jakafi/Jakafi XR sales grew 4% to $827 million. Management raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, including higher Opzelura guidance of $1.10 billion-$1.12 billion. Incyte raises 2026 sales outlook
• Positive Sentiment: Adagene dosed the first patient in a Phase 1 study combining its therapy with Incyte’s INCA33890 in colorectal cancer, providing an incremental development catalyst for Incyte’s pipeline. Adagene INCA33890 trial announcement

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Sanford C. Bernstein reissued a “market perform” rating and set a $104.00 price target on shares of Incyte in a report on Thursday, August 13th. JPMorgan Chase & Co. raised their price objective on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a report on Monday, September 28th. Truist Financial boosted their target price on Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, October 14th. Royal Bank Of Canada increased their price target on Incyte from $109.00 to $114.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Finally, Guggenheim raised their price target on Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Twelve analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $131.43.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.